10 Chinese Penny Stocks to Buy According to Analysts

Page 9 of 9

1. Adlai Nortye Ltd. (NASDAQ:ANL)

Share Price (As of December 17): $2.36

Analysts Upside: 281%

Established in 2017, Adlai Nortye Ltd. (NASDAQ:ANL) is a global clinical-stage biopharmaceutical firm that is developing differentiated, innovative immuno-oncology medicines. Adlai Nortye made its IPO on NASDAQ in September 2024. The company is involved in R&D and the development of cancer therapies. Adlai Nortye’s pipeline includes three drug candidates in the clinical stage: buparlisib (AN2025), palupiprant (AN0025), and AN4005, alongside three candidates in the preclinical stage.

AN2025 is the lead product of Adlai Nortye Ltd. (NASDAQ:ANL) which is designed to treat solid tumors. The potential treatment candidate is under Phase 3 clinical trials for patients suffering from metastatic squamous neck cancer. AN2025 could potentially become the first drug to cure metastatic squamous neck cancer patients. Furthermore, the company’s other products to treat metastatic cancer including AN4005, a first-in-class oral PD-L1 inhibitor, and AN8025, a multifunctional fusion protein that serves as a T cell and APC modulator, are also progressing in their initial trials.

Adlai Nortye Ltd. (NASDAQ:ANL) is creating an experienced team with the additions of Archie Tse, M.D., Ph.D., as the Head of Research and Development, an expert in oncology drug development, and Roger Sawhney, M.D., the newest member of Adlai’s board of directors. According to the National Cancer Institute of Health (NIH), in the US alone, the number of people suffering from metastatic breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma is projected to rise from 623,405 in 2018 to 693,452 by 2025. This shows a potential opportunity for Adlai to enter the market and make a mark.

Adlai Nortye Ltd. (NASDAQ:ANL) is focused on making a difference in curing metastatic cancer patients. AN2025 remains a key product for the company and the firm expects it to be on track to report the Phase 3 OS data in the first quarter of 2025, which would be potentially a game changer for the firm. Being a new biopharmaceutical firm with huge potential, ANL can gain massively in the long term.

While we acknowledge the potential of Adlai Nortye Ltd. (NASDAQ:ANL) to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ANL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 9 of 9